HLB Genex, Inc.

As of March 31, 2026, HLB Genex, Inc. carries a market capitalization of 74.47B, placing it among publicly traded companies globally. Its enterprise value stands at 101.04B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, HLB Genex, Inc. has 29.38M shares outstanding.

As of March 31, 2026, HLB Genex, Inc. trades at a trailing price-to-earnings ratio of 3.45. The price-to-sales ratio is 1.67, and the price-to-book ratio stands at 1.89.

As of March 31, 2026, HLB Genex, Inc. trades at an EV/EBITDA multiple of 48.06 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.28 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 72.39 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. HLB Genex, Inc. trades at an EV/FCF ratio of 7.39, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 101.04B versus a market cap of 74.47B, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, HLB Genex, Inc. maintains a current ratio of 0.82, meaning it holds 0.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 85.53, indicating elevated leverage, while an interest coverage ratio of 0.18 demonstrates limited ability to service its debt obligations.

Over the twelve months ended March 31, 2026, HLB Genex, Inc. posted a return on equity (ROE) of 69.20, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 1.63 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 15.54, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 38.77, useful for judging operating efficiency across full business cycles. The company generates approximately 583.50M in revenue per employee across its workforce of 76.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 4.33 indicates how many times HLB Genex, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, HLB Genex, Inc. recorded 916.70M in income tax expense. That works out to an effective tax rate of 4.05, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 22.63B, leaving 21.42B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, HLB Genex, Inc.'s stock has declined approximately 27.59% over the past 52 weeks. The 50-day moving average sits at 2,009.58, while the 200-day moving average is 2,332.46.

Over the twelve months ended March 31, 2026, HLB Genex, Inc. generated 44.35B in revenue and converted that into 21.42B in net income, yielding earnings per share of 497.62. EBITDA reached 2.10B, while operating income came in at 1.50B.

As of March 31, 2026, HLB Genex, Inc. holds 33.12B in cash and equivalents against 45.70B in total debt, resulting in a net debt position of 11.93B. Total book value stands at 39.44B, with working capital of -11.39B providing operational flexibility.

HLB Genex, Inc. produced 4.23B in operating cash flow over the twelve months ended March 31, 2026. After subtracting -1.53B in capital expenditures, free cash flow totaled 2.70B - equivalent to 92.46 per share.

Over the twelve months ended March 31, 2026, HLB Genex, Inc. posted a gross margin of 36.02, reflecting its pricing power and cost economics. The operating margin of 3.37 and net profit margin of 48.31 provide insight into operational efficiency.

These figures cover the twelve months ended March 31, 2026. Free cash flow yield stands at 2.44, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 16.51, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to HLB Genex, Inc. shareholders.

HLB Genex, Inc.'s most recent stock split took place on March 19, 2018 with a 1:2 split ratio.

As of March 31, 2026, HLB Genex, Inc. has an Altman Z-Score of 0.86, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.